Biopharma deals lost speed in the third quarter and are now falling behind each of the last two years, while merger and acquisition values doubled the amount from the first half of 2022. The industry completed a total of 283 deals, including licensings, collaborations and joint ventures, in Q3. They were worth a combined value of $40.98 billion, a rise of 8.3% over the second quarter but down by 28.7% from the first quarter.
While third quarter med-tech financing proceeds rose by nearly 20% over the second quarter, making it the best quarter this year, amounts raised for the first nine months of 2022 are still down by 40% in comparison with 2021.
A strong third quarter has pushed biopharma financings ahead of several pre-pandemic years, as follow-on offerings and private placements picked up the pace. IPOs and venture capital rounds dipped below prior quarters, but the overall amount raised so far this year has placed 2022 as the fifth best financing year among the last 10, ahead of both 2019 and 2017.
A strong third quarter has pushed biopharma financings ahead of several pre-pandemic years, as follow-on offerings and private placements picked up the pace. IPOs and venture capital rounds dipped below prior quarters, but the overall amount raised so far this year has placed 2022 as the fifth best financing year among the last 10, ahead of both 2019 and 2017.
RSS
